drugset / Trial / NCT05692869

A Study of Continuous Blood Pressure Monitoring in Healthy Participants

NCT05692869

Completed 24 enrolled Eli Lilly and Company
RandomizedCrossoverOpen-labelBasic science

Summary

The main purpose of this study in healthy participants is to find out whether the traditional ambulatory blood pressure monitor (ABPM) and newer wearable devices (EmbracePlus smartwatch device, Biobeat chest patch device, and Aktiia wrist device) will accurately pick up changes in blood pressure caused by 2 different medications (propranolol and pseudoephedrine). The study will last about 29 days excluding the screening period of 28 days.

Timeline

Start
2023-01-31
Primary completion
2023-04-04
Completion
2023-04-04

Drugs

EvaluationDrugModalityDoseRoute
Subject Propranolol Small molecule Oral
Subject Pseudoephedrine Small molecule Oral

Indications

No indication recorded.